The Effect of Liposomal Bupivacaine Erector Spinae Plane Block

This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.

NCT Number	NCT07667439
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions	Liposome Bupivacaine, Erector Spinae Plane Block, Postoperative Analgesia, Randomized Controlled Trial
Enrollment	148 participants
Start Date	2026-07-01
Primary Completion	2027-02-01 (estimated)
Study Completion	2027-02-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-25